TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
REPAY Stock Rises After Visa Platform Connect Collaboration 
Alibaba Shares Fall as AI Spending Hits Profit 
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO 
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Welspun Corp Shares Hit Record High on $1.8 Billion U.S. Order 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme 
Add as a preferred source on Google
LAWRENCEVILLE, N.J., May 08, 2018 -- Celsion Corporation (NASDAQ: CLSN) announced today that Michael H. Tardugno, Chairman, President and Chief Executive Officer of Celsion, will present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference being held on May 8 – 9, 2018 at Reed Smith, LLP in New York City. Mr. Tardugno’s presentation details are as follows:
Corporate Presentation:
- Date and Time: Tuesday, May 8, 2017 at 9:30 a.m. – 9:50 a.m. EDT
- Location: Room A/B
Slide Presentation Available on Celsion’s Website
To view Mr. Tardugno’s slide presentation from the event, please visit Celsion’s corporate website at http://investor.celsion.com/financial-events .
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in development for other cancer indications. The Company’s product pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: http://www.celsion.com. (CLSN-FIN).
Celsion Investor Contact Jeffrey W. Church Sr. Vice President and CFO 609-482-2455 [email protected]
